2017

A case of successful treatment of Skin Excoriation Disorder with N-Acetyl Cysteine

Nauman Khan M.D.
*Western Michigan University Homer Stryker M.D. School of Medicine*

Priya Mahajan M.D.
*Western Michigan University Homer Stryker M.D. School of Medicine*

Sadia Shaukat M.D.
*Western Michigan University Homer Stryker M.D. School of Medicine*

Matthew LaCasse D.O.
*Western Michigan University Homer Stryker M.D. School of Medicine*

Mark Kanzawa D.O.
*Western Michigan University Homer Stryker M.D. School of Medicine*

Follow this and additional works at: [http://scholarworks.wmich.edu/medicine_research_day](http://scholarworks.wmich.edu/medicine_research_day)

Part of the *Life Sciences Commons*, and the *Psychiatry Commons*

**WMU ScholarWorks Citation**


[http://scholarworks.wmich.edu/medicine_research_day/27](http://scholarworks.wmich.edu/medicine_research_day/27)
A Case of Successful Treatment of Skin Excoriation Disorder with N-Acetyl Cysteine

Nauman Khan, Priya Mahajan, Sadia Shaukat, Matthew LaCasse, Mark Kanzawa

Introduction
Excoriation (skin picking) disorder, also known as pathologic skin picking, psychogenic or neurotic excoriation, or dermatillomania is characterized as the repetitive, compulsive picking of skin leading to skin damage and distress or impairment in functioning. Excoriation disorder is a new addition to the DSM-5, separating itself from obsessive compulsive disorder and body dysmorphic disorder. Grant and colleagues reference 2 community studies examining the prevalence of skin picking disorder and found rates to be between 1.4% and 5.4% of the general population (1). DSM-5 criteria highlights failed attempts to stop or cut down on the behavior as well as excessive time or secondary impairment caused by the skin picking. Some patients spend hours each day picking, others suffer social consequences secondary to the degree of tissue damage, often found on their faces.

Treatment of skin picking disorder is based on psychotherapy, including cognitive behavioral therapy and habit reversal therapy, as well as pharmacotherapy. A recent randomized, double blind trial was conducted showing efficacy of N-acetylcysteine (1200-3000 mg/d) in reducing symptoms of excoriation disorder (3). We present a case of a middle aged patient with excoriation disorder since age 15 who experienced significant improvement after treatment augmentation with N-acetylcysteine. The patient suffered a single-use relapse of her alcohol and stimulant use disorder roughly 1 month prior to initiation of NAC. This is of importance because, although inconclusive, there are reports of NAC decreasing urges and use of cocaine in addicts.

Case Description
A 59 year-old-female suffering from 44 years of unsuccessfully treated excoriation disorder presented with symptoms of unspecified depression, OCD and stimulant use disorder. She was referred by her surgeon for psychiatric management. She had postponed a revision of her hip replacement due to self-excoriation of the right axillary lymphadenectomy site. We initiated N-acetyl cysteine as it has been shown to be effective in excoriation disorder (3). N-acetyl cysteine was initiated at 1200mg per day, titrating this to 2400mg per day. Patient was also referred for weekly cognitive behavioral therapy sessions. There has been significant improvement at the surgical site as observed during the subsequent three monthly follow ups.

Discussion
This is another case report highlighting improvement of excoriation disorder with the adjunctive use of N-acetylcysteine. N-acetylcysteine is used to treat acetaminophen overdose and to loosen mucus in cystic fibrosis. It is available over the counter in health food stores.
Currently, N-acetylcysteine is being used for other neuropsychiatric disorders including cocaine, marijuana and smoking addictions, Alzheimer’s and Parkinson’s disease, compulsive and grooming disorders, autism, bipolar disorder and schizophrenia (2). The use of N-acetylcysteine in cocaine remains inconclusive yet some reports show efficacy for reducing cravings and use (2). Our patient was in active maintenance phase of cocaine use. Little is known about the use of N-acetylcysteine in the maintenance phase of cocaine use disorder. We hope our patient will continue to benefit from potential benefits of N-acetylcysteine including reducing excoriation as well as cocaine cravings and use.

References
